Plinabulin Combo With Docetaxel Aimed at Delivering a "Double Hit" in NSCLC Trial
January 3rd 2018Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.
Combination Checkpoint Therapy Gains Ground in AML and MDS
December 29th 2017Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.
Precision Medicine Can Help Reduce "Overdiagnosis" Problem
December 27th 2017In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.
CDK4/6 Inhibitors Make Impact in HR-Positive Metastatic Breast Cancer
December 19th 2017The introduction of cyclin-dependent kinase 4/6 inhibitors has resulted in a significant paradigm shift in the treatment of hormone receptor–positive breast cancer, helping to make the new agents part of rapidly developing improvements in personalized care for patients.
Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy
December 13th 2017Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.